Robert S. Busch

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Mark Lakshmanan, Brian Rayner, Robert S. Busch et al. · The Lancet Diabetes & Endocrinology · 2018 · 635 citations

Medicine, Endocrinology, Pharmacotherapy +11

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Helena W. Rodbard, Julio Rosenstock, Luís Henrique Santos Canani et al. · Diabetes Care · 2019 · 446 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

Bernard Zinman, Vaishali Bhosekar, Robert S. Busch et al. · The Lancet Diabetes & Endocrinology · 2019 · 367 citations

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund et al. · The Lancet Diabetes & Endocrinology · 2019 · 342 citations · Full text

Medicine, Nephrology, Pharmacology +13